PRINT ISSN 1119-8362
Electronic ISSN 2659-1499

Full-text Available Online at
https://www.ajol.info/index.php/jasem
https://www.bioline.org.br/ja

J. Appl. Sci. Environ. Manage.
Vol. 28 (9) 2937-2941 September 2024

A Review on the Exploration of Genomic Approaches to Malaria Prevention and Treatment in Nigeria

[1,2*]ADEROYEJE, TG; [1]ERHUANGA, OG

*[*1]Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Medical Sciences, Edo State University, Iyamho-Uzairue, Edo State, Nigeria*
[2]Malaria Research Laboratories, Institute of Advanced Medical Research and Training (IAMRAT), College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.

**Corresponding Author Email: tope_forever@yahoo.com; aderoyeje.temitope@edouniversity.edu.ng*
**ORCHID: https://orcid.org/0000-0001-6358-0813*
**Tel: +234 (0) 8077467765*

Co-Author Email: erhuangagad@gmail.com; erhuanga.gad@edouniversity.edu.ng

ABSTRACT: Malaria poses a significant global health challenge, with nearly half a million deaths annually, predominantly in sub-Saharan Africa. Nigeria alone accounts for over 24% of global cases, with severe impacts on children under five and pregnant women. Hence, this review explores the various genomic approaches being employed in the fight against malaria, including genomic surveillance of Plasmodium parasites, genetic modification of mosquito vectors, and host genomic studies for personalized medicine by harvesting information from Online sources and libraries. Information obtained reveals that Traditional control methods—such as insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs—face challenges like drug resistance and vector adaptation. Recent advances in genomic technologies offer promising new avenues for malaria prevention and treatment by providing insights into the biology of the parasite, mosquito vector, and human host.

DOI: https://dx.doi.org/10.4314/jasem.v28i9.40

Cite this Article as: ADEROYEJE, T. G; ERHUANGA, O. G. (2024). A Review on the Exploration of Genomic Approaches to Malaria Prevention and Treatment in Nigeria. *J. Appl. Sci. Environ. Manage.* 28 (9) 2937-2941

Dates: Received: Received: 07 July 2024; Revised: 15 August 2024; Accepted: 19 August 2024 Published: 05 September 2024

Keywords: Malaria; Genomic; Prevention; Treatment; Plasmodium; Mosquitoes

Malaria remains one of the most significant public health challenges worldwide, causing nearly half a million deaths annually, primarily in sub-Saharan Africa. Nigeria bears a substantial burden of malaria, contributing over 24% of global cases, with severe impacts on children under five and pregnant women (WHO, 2020). Traditional methods of control, including insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs, have made considerable impacts but face challenges such as drug resistance and vector adaptation. Advances in genomic technologies have provided new avenues for malaria prevention and treatment by providing insights into the biology of the parasite, the mosquito vector, and the human host, offering the potential for novel interventions to reduce the burden of this disease. This review explores the various genomic approaches being employed in the fight against malaria, including genomic surveillance of Plasmodium parasites, genetic modification of mosquito vectors, and host genomic studies for personalized medicine.

Genomic Surveillance of Plasmodium Parasites: Genomic surveillance involves the collection and analysis of genomic data from Plasmodium species to

**Corresponding Author Email: tope_forever@yahoo.com; aderoyeje.temitope@edouniversity.edu.ng*
**ORCHID: https://orcid.org/0000-0001-6358-0813*
**Tel: +234 (0) 8077467765*

monitor drug resistance, track transmission patterns, and identify potential targets for new therapeutics.

Genomic Insight into the Malaria Parasite: The Plasmodium genus, particularly P. falciparum and P. vivax, is responsible for most malaria cases. The sequencing of the P. falciparum genome in 2002 marked a significant milestone, providing a comprehensive blueprint of the parasite's biology (Gardner *et al*., 2002). Genomic studies have since identified key genes involved in drug resistance, such as pfcrt and pfmdr1, and targets for new antimalarial drugs (Fidock *et al*., 2000). Whole-genome sequencing (WGS) has facilitated the tracking of parasite populations, enabling the identification of genetic variations associated with drug resistance and transmission patterns (Amato *et al*., 2016). For instance, the spread of artemisinin resistance in Southeast Asia has been mapped through genomic surveillance, aiding in the containment of resistant strains (Ménard *et al*., 2016).

Vector Genomics: The primary vectors of malaria are Anopheles mosquitoes. The Anopheles gambiae genome was sequenced in 2002, providing insights into mosquito biology and vector control strategies (Holt *et al*., 2002). Genomic approaches have identified insecticide resistance markers, such as mutations in the voltage-gated sodium channel gene, enabling the development of diagnostic tools for resistance monitoring (Ranson *et al*., 2011). Gene editing technologies, such as CRISPR-Cas9, have opened new avenues for vector control. Gene drive systems, which promote the inheritance of specific genes, have been engineered to reduce mosquito populations or render them incapable of transmitting the parasite (Kyrou *et al*., 2018). These innovative strategies, however, raise ecological and ethical concerns that must be addressed through rigorous testing and regulatory frameworks.

Human Genomics and Malaria: The human genome also plays a critical role in malaria susceptibility and treatment responses. Certain genetic traits, such as the sickle cell trait (HbS) and glucose-6-phosphate dehydrogenase (G6PD) deficiency, confer resistance to malaria but can also lead to complications when exposed to certain antimalarial drugs (Carter and Mendis, 2002). Understanding these genetic factors is crucial for personalized medicine approaches in malaria treatment. Genome-wide association studies (GWAS) have identified loci associated with severe malaria, providing potential targets for therapeutic interventions and vaccine development (Malaria Genomic Epidemiology Network, 2015). Additionally, advancements in transcriptomics and proteomics are shedding light on the host immune response to malaria, guiding the design of more effective vaccines (Teo *et al*., 2018).

Genomic Approaches to Vaccine Development: Vaccine development has been a significant focus of genomic research. The RTS,S/AS01 (Mosquirix) vaccine, the first malaria vaccine to receive WHO endorsement, was developed using genomic data to identify and target the circumsporozoite protein (CSP) of P. falciparum (RTS,S Clinical Trials Partnership, 2015). Genomics continues to play a pivotal role in the search for more effective vaccines, with efforts to identify new antigenic targets and understand the genetic basis of immune evasion by the parasite.

Drug Resistance Monitoring: One of the critical applications of genomic surveillance is the monitoring of antimalarial drug resistance. The emergence of resistance to drugs such as chloroquine and artemisinin has necessitated continuous surveillance (Trape and Pison, 2020). Whole-genome sequencing (WGS) allows researchers to identify genetic mutations associated with resistance. For instance, mutations in the Kelch 13 (K13) gene have been linked to artemisinin resistance in Plasmodium falciparum (Ariey *et al*., 2014). By tracking these mutations, health authorities and healthcare providers can implement timely interventions to mitigate the spread of resistant strains.

Transmission Dynamics: Genomic data also provide insights into the transmission dynamics of malaria. High-resolution genomic studies can reveal patterns of parasite spread within and between populations, helping to identify hotspots of transmission (Manske *et al*., 2012). This information is crucial for targeted interventions and resource allocation. For example, a study in Southeast Asia used genome-wide data to trace the origins and spread of artemisinin-resistant P. falciparum, highlighting the importance of international collaboration in controlling malaria (Miotto *et al*., 2015). Deploying genomic data to monitor transmission dynamics of the malaria parasite in Nigeria will significantly improve the treatment of index cases and lower the overall burden of malaria on the population and economy.

Genetic Modification of Mosquito Vectors: Genetic modification of Anopheles mosquitoes, the primary vectors of malaria, represents a promising strategy for reducing malaria transmission. This approach includes gene drive technologies and the release of genetically modified mosquitoes.

Gene Drive Technologies: Gene drives are genetic engineering techniques that promote the inheritance of a particular gene to increase its prevalence in a population. This method can be used to spread genes that confer resistance to Plasmodium infection in mosquito populations (Burt, 2014). CRISPR-Cas9 technology has been utilized to develop gene drives targeting the reproductive capabilities of Anopheles mosquitoes, reducing their populations and consequently lowering malaria transmission rates (Kyrou *et al*., 2018).

Release of Genetically Modified Mosquitoes: Another approach involves the release of genetically modified mosquitoes that are either sterile or carry genes conferring resistance to Plasmodium. Field trials in several countries have shown promising results. For instance, the release of sterile male mosquitoes has led to significant reductions in mosquito populations in areas of Brazil and Burkina Faso (Carballar-Lejarazú and James, 2017). Additionally, mosquitoes engineered to be resistant to Plasmodium have been developed, offering a potential long-term solution to malaria transmission (Hammond *et al*., 2016).

Host Genomic Studies and Personalized Medicine: Understanding the genetic factors that influence an individual's susceptibility to malaria can lead to more effective treatments and preventive measures. Host genomic studies have identified several genetic variants associated with malaria resistance and susceptibility.

Genetic Variants and Malaria Resistance: Certain genetic traits, such as the sickle cell trait, provide a protective effect against malaria (Weatherall and Clegg, 2001). Genome-wide association studies (GWAS) have identified other genetic variants associated with reduced malaria susceptibility, such as mutations in the glucose-6-phosphate dehydrogenase (G6PD) gene and the Duffy antigen receptor for chemokines (DARC) gene (Malaria Genomic Epidemiology Network, 2015). These findings could inform the development of new therapeutic strategies and vaccines.

Personalized Medicine: Personalized medicine, which tailors treatment to an individual's genetic makeup, is becoming increasingly feasible with advancements in genomic technologies. Pharmacogenomics, the study of how genes affect a person's response to drugs, can optimize antimalarial drug efficacy and reduce adverse effects (Teo *et al*., 2018). For example, genetic testing can identify individuals with G6PD deficiency, who are at risk of hemolysis when treated with certain antimalarials, ensuring safer treatment options (Carter and Mendis, 2002).

Challenges and Future Directions: Despite the promise of genomic approaches, several challenges remain. The complexity of the malaria parasite's life cycle, genetic diversity, and the interplay between host, parasite, and vector genomes necessitate comprehensive and integrative research efforts. Ethical considerations and the potential ecological impact of genomic interventions, particularly gene drives, require careful assessment and international cooperation. Future research should focus on enhancing genomic surveillance systems, developing robust and scalable gene editing technologies, and integrating multi-omics data to unravel the intricate biology of malaria. Collaborative efforts and sustained funding will be crucial in translating genomic insights into practical solutions for malaria prevention and treatment.

Conclusion: Genomic approaches have revolutionized our understanding of malaria and hold great promise for developing innovative prevention and treatment strategies. From mapping parasite resistance to engineering vector populations and personalizing human therapies, genomics is at the forefront of the fight against malaria. Continued investment in genomic research and ethical considerations will be essential in leveraging these technologies to achieve malaria eradication.

REFERENCES

Amato, RO; Miotto, CJ; Woodrow, JA; Sinha, I; Campino S; Auburn, S; MacInnis, B; Rockett, KA; Clark, TG; Kwiatkowski, DP (2016). Genetic Markers Associated with Dihydroartemisinin-Piperaquine Failure in Plasmodium falciparum Malaria in Cambodia: A Genotype-Phenotype Association Study. *The Lancet Infect. Dis.* 16 (3): 280-288. https://doi.org/10.1016/S1473-3099(15)00481-8.

Ariey, FB; Witkowski, C; Amaratunga, J; Beghain, AC; Langlois, N; Khim, S; Kim, V; Duru, C; Bouchier, L; Ma, P; Lim, R; Leang, S; Duong, S; Sreng, S; Suon, CM; Chuor, DM; Bout, S; Menard, W; Rogers, O; Mercereau-Puijalon, O (2014). A Molecular Marker of Artemisinin-Resistant Plasmodium falciparum Malaria. *Nature* 505 (7481): 50-55. https://doi.org/10.1038/nature12876.

Burt, A (2014). Heritable Strategies for Controlling Insect Vectors of Disease. *Philos. Trans. R. Soc. B*

Biol. Sci. 369 (1645): 20130432. https://doi.org/10.1098/rstb.2013.0432.

Carballar-Lejarazú, R; James, AA (2017). Population Modification of Anopheline Species to Control Malaria Transmission**.** *Pathog. Glob. Health.* 111 (8): 424-435. https://doi.org/10.1080/20477724.2017.1375001.

Carter, R; Mendis, KN (2002). Evolutionary and Historical Aspects of the Burden of Malaria. *Clin. Microbiol. Rev.* 15 (4): 564-594. https://doi.org/10.1128/CMR.15.4.564-594.2002.

Fidock, DA; Nomura, T; Talley, AK; Cooper, RA; Dzekunov, SM; Ferdig, MT; Udeinya, IJ; LeBlanc, RE; Cravo, PV; Macomber, PB (2000). Mutations in the pfcrt Gene and Chloroquine Resistance in Plasmodium falciparum. *Mol. Cell.* 6 (4): 861-871. https://doi.org/10.1016/S1097-2765(05)00077-9.

Gardner, MJ; Hall, N; Fung, E; White, O; Berriman, M; Hyman, RW; Carlton, JM; Pain, A; Nelson, KE; Bowman, S; Paulsen, IT; James, K; Eisen, JA; Rutherford, K; Salzberg, SL; Craig, A; Kyes, S; Chan, MS; Nene, V; Shallom, B; Suh, J; Peterson, S; Angiuoli, M; Pertea, J; Allen, J; Selengut, D; Haft, MW; Mather, AB; Vaidya, DM; Martin, AH; Fairlamb, MJ; Fraunholz, DS; Roos, SA; Ralph, GI; McFadden, LM; Cummings, GM; Subramanian, C; Mungall, JC; Venter, DJ; Carucci, SL; Hoffman, C; Newbold, RW; Davis, CMF; Barrell, B (2002). Genome Sequence of the Human Malaria Parasite Plasmodium falciparum. *Nature* 419 (6906): 498–511. https://doi.org/10.1038/nature01097.

Hammond, A.K; Kyrou, M; Bruttini, A; North, R; Galizi, X; Karlsson, N; Kranjc, FM; Carpi, RD; Crisanti, A (2016). The Creation and Selection of Mutations Resistant to a Gene Drive Over Multiple Generations in the Malaria Mosquito. *PLoS Genet.* 12 (10): e1006060. https://doi.org/10.1371/journal.pgen.1006060.

Holt, RA; Subramanian, GM; Halpern, A; Sutton, GG; Charlab, R; Nusskern, DR; Wincker, P; Clark, AG; Ribeiro, JM; Wides, R (2002). The Genome Sequence of the Malaria Mosquito Anopheles gambiae. *Science* 298 (5591): 129-149. https://doi.org/10.1126/science.1076181.

Howes, RE; Battle, KE; Mendis, KN; Smith, DL; Cibulskis, RE; Baird, JK; Hay, SI (2016). Global Epidemiology of Plasmodium vivax. *Am. J. Trop. Med. Hyg.* 95 (6 Suppl): 15-34. https://doi.org/10.4269/ajtmh.16-0141.

Kyrou, K.; Hammond, AM; Galizi, R; Kranjc, N; Burt, A; Beaghton, AK; Nolan, T; Crisanti, A (2018). A CRISPR–Cas9 Gene Drive Targeting doublesex Causes Complete Population Suppression in Caged Anopheles gambiae Mosquitoes. *Nat. Biotechnol.* 36 (11): 1062-1066. https://doi.org/10.1038/nbt.4245.

Malaria Genomic Epidemiology Network (2015). A Global Network for Investigating the Genomic Epidemiology of Malaria. *Nature* 526 (7571): 253-257. https://doi.org/10.1038/nature15535.

Manske, M; Miotto, O; Campino, S; Auburn, S; Almagro-Garcia, J; Maslen, G; O'Brien, J; Djimde, A; Doumbo, O; Zongo, I; Ouedraogo, JB; Michon, P; Mueller, I; Siba, P; Nzila, A; Borrmann, S; Kiara, SM; Marsh, K; Jiang, H; Kwiatkowski, DP (2012). Analysis of Plasmodium falciparum Diversity in Natural Infections by Deep Sequencing. *Nature* 487 (7407): 375-379. https://doi.org/10.1038/nature11174.

Ménard, D; Khim, N; Beghain, J; Adegnika, AA; Shafiul-Alam, M; Rahim, SA; Barnadas, C; Li, J; Bouchier, C; Ménard, S (2016). A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. *N. Engl. J. Med.* 374 (25): 2453-2464. https://doi.org/10.1056/NEJMoa1513137.

Miotto, O; R. Amato, EA; Ashley, B; MacInnis, J; Almagro-Garcia, C; Amaratunga, P; Lim, D; Mead, DO; Dhorda, M (2015). Genetic Architecture of Artemisinin-Resistant Plasmodium falciparum. *Nat. Genet.* 47 (3): 226-234. https://doi.org/10.1038/ng.3189.

RTS,S Clinical Trials Partnership (2015). Efficacy and Safety of RTS,S/AS01 Malaria Vaccine with or without a Booster Dose in Infants and Children in Africa: Final Results of a Phase 3, Individually Randomised, Controlled Trial. *The Lancet* 386 (9988): 31-45. https://doi.org/10.1016/S0140-6736(15)60721-8.

Ranson, H; Jensen, B; Vulule, JM; Wang, X; Hemingway, J; Collins, FH (2000). Identification of a Point Mutation in the Voltage-Gated Sodium Channel Gene of Kenyan Anopheles gambiae Associated with Resistance to DDT and Pyrethroids. *Insect Mol. Biol.* 9 (5): 491-497. https://doi.org/10.1046/j.1365-2583.2000.00209.x.

Teo, A; Feng, G; Brown, GV; Beeson, JG; Rogerson, SJ (2018). Functional Antibodies and Protection from Malaria in Children. *Trends Parasitol.* 34 (1): 2-4. https://doi.org/10.1016/j.pt.2017.10.005.

Trape, JF; Pison, G (2020). Long-Term Changes in the Risk of Malaria among Children and Adults in Rural Senegal: 1990-2010. *Glob. Health Action* 13 (1): 1732666. https://doi.org/10.1080/16549716.2020.1732666.

Weatherall, DJ; Clegg, JB (2001). Inherited Haemoglobin Disorders: An Increasing Global Health Problem. *Bull. World Health Organ* 79 (8): 704-712. https://www.scielosp.org/article/bwho/2001.v79n8/704-712/en/.

World Health Organization. *World Malaria Report 2020*. Geneva: World Health Organization, 2020. https://www.who.int/publications/i/item/9789240015791.